Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety effects and handling precautions are supported, including dry mouth, drowsiness/somnolence, dizziness/vertigo, blurred vision from eye contact, confusion/disorientation/cognitive impairment, urinary retention/trouble urinating, and increased risks with CNS/anticholinergic drugs. However, several claims are not fully supported as written (e.g., “often used”/relative likelihood language, and eye-irritation/trouble urinating descriptors beyond label wording), and some combination-risk claims go beyond the label’s stated outcomes.
Category Scores
Accurate Statements
Scopolamine patch side effects mainly come from its anticholinergic effects.
Label states scopolamine is an anticholinergic and can cause drowsiness, dilate pupils, and depress motor function (12.1).
Commonly reported scopolamine patch side effects include dry mouth.
Motion sickness: most common adverse reaction was dry mouth (6.1). PONV: common adverse reactions include dry mouth (6.1).
Commonly reported scopolamine patch side effects include blurred vision.
Motion sickness: less common included blurred vision and dilation of the pupils (6.1). PONV: common adverse reactions include visual impairment (6.1).
Commonly reported scopolamine patch side effects include dizziness.
Postmarketing: ear and labyrinth disorders include vertigo (6.2). Warnings: discontinuation may result in dizziness (5.5).
Commonly reported scopolamine patch side effects include drowsiness.
Motion sickness: less common included drowsiness (6.1). Warnings: can cause drowsiness (5.2).
Scopolamine patches can cause confusion or difficulty concentrating.
Warnings: can cause disorientation and confusion (5.2). PONV table includes confusion (6.1).
Less common but more serious scopolamine patch effects can include trouble urinating.
Warnings: can cause urinary retention; discontinue if difficulty in urination develops (5.4).
Less common but more serious scopolamine patch effects can include severe eye-related symptoms if the medication irritates the eye.
Warnings: blurred vision if comes in contact with the eyes (5.6) and MRI/eye disorders list includes eyelid irritation and angle closure glaucoma (6.2 and 5.1).
Confusion or disorientation is a known concern with scopolamine patches.
Warnings: can cause drowsiness, disorientation, and confusion (5.2).
Blurred vision can happen with scopolamine due to anticholinergic effects on the eye and pupil.
Warnings: temporary dilation of the pupils resulting in blurred vision if it comes in contact with the eyes (5.6). Label also includes dilation of the pupils (6.1).
Eye exposure during patch handling can increase the risk of eye irritation symptoms.
Instructions: after handling, wash hands thoroughly to prevent eye contact; blurred vision occurs if it comes in contact with the eyes (2.1 and 5.6). Postmarketing includes eyelid irritation (6.2).
Side effects typically lessen after a scopolamine patch is removed.
Warnings: discontinuation effects onset generally 24 hours or more after removal and list withdrawal symptoms (5.5), implying medication effect changes after removal (timing supported).
The full effect of a scopolamine patch can take some time to wear off after removal.
Warnings: onset of withdrawal symptoms is generally 24 hours or more after the transdermal system has been removed (5.5).
Scopolamine can have additive effects with other medicines that cause drowsiness or have anticholinergic properties.
Drug interactions: concomitant use with drugs causing CNS adverse reactions (e.g., sedatives) or with anticholinergic properties may potentiate scopolamine effects (7.1).
Extra caution is advised for people with glaucoma (especially narrow-angle glaucoma) when using scopolamine patches.
Contraindication: angle closure glaucoma (4). Warnings: scopolamine mydriatic effect may cause increase in intraocular pressure resulting in acute angle closure glaucoma (5.1).
Wash hands after touching a scopolamine patch to prevent accidental eye exposure.
Application/removal instructions: after application on dry skin, wash hands thoroughly and dry (2.1). Blurred vision warning advises wash hands after handling (5.6).
Removing a scopolamine patch is recommended if troubling blurred vision, confusion, or urinary trouble develops.
Warnings: advise to immediately remove the transdermal system for acute angle closure glaucoma symptoms (5.1); discontinue if signs of cognitive impairment develop (5.2); discontinue if difficulty in urination develops (5.4). Blurred vision warning supports eye-contact handling to reduce blurred vision risk (5.6).
Unsupported Statements
Scopolamine is often used as a transdermal patch to prevent nausea and motion sickness.
The label provided includes the indication that the system is indicated for prevention of nausea/vomiting associated with motion sickness, but it does not support the word choice “often used.”
Commonly reported scopolamine patch side effects mainly come from its anticholinergic effects.
While the label supports anticholinergic mechanism and related effects, it does not explicitly state that side effects “mainly” come from anticholinergic effects.
Commonly reported scopolamine patch side effects include constipation.
No constipation adverse reaction is stated in the provided excerpts (dry mouth, dizziness/vertigo, drowsiness/somnolence, blurred vision/visual impairment, confusion, urinary retention/difficulty urination are supported, but constipation is not listed).
Combining scopolamine with other drowsiness-causing or anticholinergic medicines can increase the risk of confusion.
The label states concomitant use may potentiate CNS adverse reactions and may increase risk of CNS adverse reactions (7.1, 7.2), but it does not specifically list “confusion” as an interaction outcome.
Combining scopolamine with other drowsiness-causing or anticholinergic medicines can increase the risk of constipation.
The label excerpt does not mention constipation as an adverse reaction or as a specific interaction outcome.
Combining scopolamine with other drowsiness-causing or anticholinergic medicines can increase the risk of blurred vision.
The label excerpt states CNS adverse reactions and anticholinergic risks (including urinary retention/intestinal obstruction) but does not specifically state blurred vision risk with concomitant drugs.
Confusion or difficulty concentrating with scopolamine patches is more likely in older adults or in people sensitive to anticholinergic medicines.
The label supports increased risk of neurologic/psychiatric adverse reactions in elderly (8.5). It does not support the broader phrase “people sensitive to anticholinergic medicines.”
Extra caution is advised for people with urinary retention or prostate enlargement when using scopolamine patches.
The provided excerpt mentions urinary retention and urinary difficulty (5.4) but does not explicitly mention “prostate enlargement.”
Extra caution is advised for people with conditions that can be worsened by anticholinergic medications when using scopolamine patches.
The label excerpt supports anticholinergic effects and drug interactions/monitoring, but the provided text does not include this exact broad caution statement.
Side effects typically lessen after the patch is removed, because the patch delivers medication over time.
The label supports delivery over ~3 days (2.1, 12.3) and provides withdrawal timing (5.5), but it does not explicitly connect “side effects lessen because the patch delivers medication over time.”
Contradictions
Low
AI Statement
Extra caution is advised for people with glaucoma (especially narrow-angle glaucoma) when using scopolamine patches.
Label Reference
Contraindicated in angle closure glaucoma (4); Warnings advise removal and contact provider for acute angle closure glaucoma symptoms (5.1).
Important Omissions
No mention of contraindication to angle closure glaucoma/hypersensitivity (4) beyond caution language.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims align with label-listed adverse reactions and warnings, but unsupported/overbroad statements (e.g., constipation; specific interaction outcomes for confusion/blurred vision; “sensitivity to anticholinergic medicines”; and prostate enlargement) could mislead readers about likelihood or specific risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple safety statements include “common/commonly,” interaction-specific outcomes, and constipation/prostate-enlargement details that are not supported by the provided label excerpts.
Suggested Improvement
Replace “often/commonly” and interaction-specific outcome claims with label-supported wording (e.g., “may potentiate CNS adverse reactions,” “may increase risk of CNS adverse reactions,” and discontinue for cognitive impairment signs and difficulty urinating). Remove or qualify unsupported claims (constipation; prostate enlargement; sensitivity to anticholinergic medicines) unless supported by additional label text.